Class-Action Status for Rezulin Cases Rejected
Pfizer Inc. won’t have to face a nationwide class-action suit over its Rezulin diabetes drug that’s been linked to liver problems, a federal judge ruled.
U.S. District Judge Lewis A. Kaplan rejected a bid by plaintiffs to combine claims from more than 2 million former Rezulin users into a single case in federal court in New York. Kaplan said consumers’ problems with the drug were too individualized to warrant treatment as a class.
The decision comes after a California judge’s ruling this year that Pfizer and its Warner-Lambert Co. unit weren’t subject to a class-action suit claiming the drug’s advertising misled consumers about health risks.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
